First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study (Q35705210)
Jump to navigation
Jump to search
scientific article published on 10 January 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study |
scientific article published on 10 January 2012 |
Statements
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study (English)
Auxiliadora Gómez-España
Bartomeu Massutí
Javier Sastre
Albert Abad
Manuel Valladares
Fernando Rivera
Maria J Safont
Purificación Martínez de Prado
Manuel Gallén
Encarnación González
Eugenio Marcuello
Manuel Benavides
Carlos Fernández-Martos
Ferrán Losa
Pilar Escudero
Antonio Arrivi
Andrés Cervantes
Rosario Dueñas
Amelia López-Ladrón
Marta Llanos
Antonio Antón
Enrique Aranda
Spanish Cooperative Group for the Treatment of Digestive Tumors
10 January 2012
1 reference
1 reference
1 reference
1 reference